Government Pension Fund Global (Norway) decreased its stake in Cipla Limited from 1.37% to 1.30%, selling 639,014 shares.
A leading pharmaceutical manufacturer, Cipla develops and markets branded and generic formulations alongside active pharmaceutical ingredients across multiple therapeutic areas. Established in 1935, the company operates manufacturing facilities across India and internationally, serving both domestic and global markets. Cipla's distinctive strength lies in its integrated business model combining formulation development with API production, enabling cost-efficient drug manufacturing, distribution, and accessibility to patients worldwide.
Norway's sovereign wealth fund, managed by Norges Bank Investment Management. World's largest SWF with over USD 2 trillion in assets, invested across 8,700+ companies globally including Indian equities.